-M A Walter Researcher Activity Profile

Research Author Detailed Information 

M A Walter Publication Rate By Year

M A Walter has published 1 paper(s) in 1984, 1 paper(s) in 1998, 3 paper(s) in 2006, 4 paper(s) in 2007, 2 paper(s) in 2008, for a total of 11 research publications in total.

M A Ma Walter Author Information

LAST NAME: walter

FIRST NAME: M A

INITIALS: ma

AFFILIATION:

Papers

M A Walter's Publication Record

1. The forkhead/winged helix gene Mf1 is disrupted in the pleiotropic mouse mutation congenital hydrocephalus. Year Published: 1998
Howard Hughes Medical Institute, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2175, USA.
2. Functional interactions between FOXC1 and PITX2 underlie the sensitivity to FOXC1 gene dose in Axenfeld-Rieger syndrome and anterior segment dysgenesis. Year Published: 2006
Department of Ophthalmology, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7. fberry@ualberta.ca
3. FGF19 is a target for FOXC1 regulation in ciliary body-derived cells. Year Published: 2006
Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada.
4. Coregistered iodine-131 single photon emission computed tomograpy/computed tomography reveals dedifferentiation in a metastatic follicular thyroid carcinoma. Year Published: 2006
Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland., Institute of Nuclear Medicine, University Hospital Basel, University Hospital Basel, Basel, Switzerland.
5. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. Year Published: 2007
Department of Neurology, University Medical Center Freiburg, Germany.
6. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. Year Published: 2007
Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland. m.a.walter@gmx.net
7. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Year Published: 2007
Institute of Nuclear Medicine, Division of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital Basel, University of Basel, Petersgraben 4, Basel, Switzerland.
8. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Year Published: 2007
Institute of Nuclear Medicine, Division of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital Basel, University of Basel, Petersgraben 4, Basel, Switzerland.
9. FOXC1 is required for cell viability and resistance to oxidative stress in the eye through the transcriptional regulation of FOXO1A. Year Published: 2008
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
10. FOXC1 is required for cell viability and resistance to oxidative stress in the eye through the transcriptional regulation of FOXO1A. Year Published: 2008
Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada. fberry@ualberta.ca
11. Glomerular & vascular changes in malignant hypertension. Year Published: 1984